ASSAY SYSTEM FOR EVALUATING CELLULAR ANTISENSE DELIVERY
用于评估细胞反义递送的测定系统
基本信息
- 批准号:2602743
- 负责人:
- 金额:$ 9.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-04-01 至 2000-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (Adapted from Investigator's Abstract): A conventional
functional assay system for assessing cellular delivery of an antisense
agent is usually based on down-regulation of the translational step in gene
expression by the antisense agent. The procedure suffers from several
theoretical as well as practical problems. In the proposed study, the PI
plans to devise a cellular assay system in which an antisense agent
up-regulates the protein synthesis in such a way that a new protein,
luciferase in the present case, begins to appear as the antisense agent
enters the cell. The system can be developed by transfecting cells with a
luciferase plasmid with aberrant splicing that can be corrected by an
antisense agent.
At least three different recombinant luciferase plasmids will be prepared by
inserting a mutant human b-globin intron 2 at different locations of a
luciferase plasmid pTRE-LUC from a commercial source. Recently, the PI has
shown that the aberrant splicing caused by the mutant intron can be
corrected by a 17-mer antisense targeted to its 5' splice site. In a
preliminary experiment, the PI found that the HeLa cells transfected by the
recombinant luciferase plasmid indeed produce luciferase when the oligomer
was introduced to the cell by Lipofectamine, clearly establishing
feasibility. In addition to HeLa cells, fibroblast cell line NIH/3T3 and
monocyte-derived Raw 264.7 cells will be transfected with the plasmid.
These cells will demonstrate different endocytic activities. When
developed, the present system will be most useful and could become a
universal assay system in objectively comparing various novel strategies of
antisense/antigen delivery. Due to its intrinsic nature, however, ther
system cannot be used with an oligomer that activates RNase H. However, this
is not a limitation.
描述(改编自研究者摘要):一种常规的
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MOO J CHO其他文献
MOO J CHO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MOO J CHO', 18)}}的其他基金
pH- SENSITIVE BIS-DETERGENTS FOR MACROMOLECULAR DELIVERY
用于大分子输送的 pH 敏感双去污剂
- 批准号:
6776804 - 财政年份:2004
- 资助金额:
$ 9.63万 - 项目类别:
pH- SENSITIVE BIS-DETERGENTS FOR MACROMOLECULAR DELIVERY
用于大分子输送的 pH 敏感双去污剂
- 批准号:
6872986 - 财政年份:2004
- 资助金额:
$ 9.63万 - 项目类别:
TARGETING ENDOGENOUS ANTIBODIES TO OVARIAN CARCINOMA
针对卵巢癌的内源性抗体
- 批准号:
6623365 - 财政年份:2002
- 资助金额:
$ 9.63万 - 项目类别:
TARGETING ENDOGENOUS ANTIBODIES TO OVARIAN CARCINOMA
针对卵巢癌的内源性抗体
- 批准号:
6465181 - 财政年份:2002
- 资助金额:
$ 9.63万 - 项目类别:
ASSAY SYSTEM FOR EVALUATING CELLULAR ANTISENSE DELIVERY
用于评估细胞反义递送的测定系统
- 批准号:
2900929 - 财政年份:1998
- 资助金额:
$ 9.63万 - 项目类别:
相似海外基金
Temporal and spatial localization of TRAPP subunits during the cell cycle of HeLa cells
HeLa 细胞细胞周期中 TRAPP 亚基的时空定位
- 批准号:
432807-2012 - 财政年份:2012
- 资助金额:
$ 9.63万 - 项目类别:
University Undergraduate Student Research Awards
Analysis of the regulation of asymmetric cell division by using the artificially induced polarization of HeLa cells.
利用HeLa细胞的人工诱导极化分析不对称细胞分裂的调控。
- 批准号:
24657088 - 财政年份:2012
- 资助金额:
$ 9.63万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
The internalization mechanism of Ureaplasma parvum in HeLa cells.
小脲原体在 HeLa 细胞中的内化机制。
- 批准号:
23791241 - 财政年份:2011
- 资助金额:
$ 9.63万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
MicroRNA analysis of cervical cancer HeLa cells resistant to gene silencing of human papillomavirus (HPV) E6 and E7 onco
宫颈癌 HeLa 细胞对人乳头瘤病毒 (HPV) E6 和 E7 基因沉默具有抗性的 MicroRNA 分析
- 批准号:
nhmrc : 519809 - 财政年份:2008
- 资助金额:
$ 9.63万 - 项目类别:
Early Career Fellowships
Identification and characterization of new genetic responses in escherichia coli and human (HeLa) cells
大肠杆菌和人类 (HeLa) 细胞中新遗传反应的鉴定和表征
- 批准号:
3222-2002 - 财政年份:2003
- 资助金额:
$ 9.63万 - 项目类别:
Discovery Grants Program - Individual
Identification and characterization of new genetic responses in escherichia coli and human (HeLa) cells
大肠杆菌和人类 (HeLa) 细胞中新遗传反应的鉴定和表征
- 批准号:
3222-2002 - 财政年份:2002
- 资助金额:
$ 9.63万 - 项目类别:
Discovery Grants Program - Individual
Identification and characterization of new genetic responses ub escgerucgua ciku abd gynab (HeLa) cells
新遗传反应 ub escgerucgua ciku abd gynab (HeLa) 细胞的鉴定和表征
- 批准号:
3222-1998 - 财政年份:2001
- 资助金额:
$ 9.63万 - 项目类别:
Discovery Grants Program - Individual
Identification and characterization of new genetic responses ub escgerucgua ciku abd gynab (HeLa) cells
新遗传反应 ub escgerucgua ciku abd gynab (HeLa) 细胞的鉴定和表征
- 批准号:
3222-1998 - 财政年份:2000
- 资助金额:
$ 9.63万 - 项目类别:
Discovery Grants Program - Individual
Identification and characterization of new genetic responses ub escgerucgua ciku abd gynab (HeLa) cells
新遗传反应 ub escgerucgua ciku abd gynab (HeLa) 细胞的鉴定和表征
- 批准号:
3222-1998 - 财政年份:1999
- 资助金额:
$ 9.63万 - 项目类别:
Discovery Grants Program - Individual
Identification and characterization of new genetic responses ub escgerucgua ciku abd gynab (HeLa) cells
新遗传反应 ub escgerucgua ciku abd gynab (HeLa) 细胞的鉴定和表征
- 批准号:
3222-1998 - 财政年份:1998
- 资助金额:
$ 9.63万 - 项目类别:
Discovery Grants Program - Individual